Ten years of Croatian national guidelines for use of eicosapentaenoic acid and Megestrol (cas 3562-63-8) acetate in cancer cachexia syndrome – Evaluation of awareness and implementation among Croatian oncologists
-
Add time:07/11/2019 Source:sciencedirect.com
SummaryBackground & aimsCancer cachexia (CC) syndrome and anorexia–cachexia syndrome are common terms used to describe changes in metabolism with increased inflammatory activity and can progressively develop through various stages such as pre-cachexia; cachexia; and refractory cachexia. Therefore in year 2007 Croatian guidelines for use of eicosapentaenoic acid and Megestrol (cas 3562-63-8) acetate in cancer cachexia syndrome were published. Aim of this study was to assess the awareness and implementation of Croatian guidelines for use of eicosapentaenoic acid (EPA) and megestrol acetate (MA) into clinical practice among Croatian oncologists approximately 10 years after the publication, but also to point out the importance of adequate recognition and treatment of CC.
We also recommend Trading Suppliers and Manufacturers of Megestrol (cas 3562-63-8). Pls Click Website Link as below: cas 3562-63-8 suppliers
Prev:Correlation between Fe content and z value in Sm(CobalFexCu0.06Zr0.025)z permanent magnets
Next:Synthesis and pharmacological characterization of novel N-(trans-4-(2-(4-(benzo[d]isothiazol-3-yl)piperazin-1-yl)ethyl)cyclohexyl)amides as potential multireceptor atypical antipsychotics) - 【Back】【Close 】【Print】【Add to favorite 】
-
Health and Chemical more >